Identification of oncogenes from myeloid leukaemias by retroviral expression cloning

大多数髓性白血病的治疗成功率仍然相对较低，总体5年生存率为40-50%。因此，显然需要改进诊断，特别是治疗。一个重要的和相对较新的方法是针对导致这些疾病的特定分子和遗传改变。这需要鉴定这些改变，特别是引起或促成各种形式的骨髓性白血病的癌基因（“癌基因”）。然而，在许多情况下（高达50%），涉及的关键癌基因没有和-或不能确定使用现有的方法。该项目旨在开发和应用一种称为“逆转录病毒表达克隆”的强大技术，用于鉴定与髓性白血病有关的癌基因。从本质上讲，我们的方法是根据它们的功能从髓性白血病样品中鉴定癌基因-也就是说，凭借它们诱导培养物中血液来源细胞的失调或不受控制的生长的能力。

The success rates for treatment of most myeloid leukaemias remain relatively poor, with 5-year survival rates of 40-50% overall. Thus there is a clear need for improvements in diagnosis and particularly treatment. An important and relatively new approach for doing this is to target the specific molecular and genetic alterations that lead to these diseases. This requires the identification of these alterations, particularly the oncogenes ('cancer genes') that cause or contribute to the various forms of myeloid leukaemia. However in many cases (up to 50%), the key oncogenes involved in have not and-or cannot be identified using current methods. This project aims to develop and apply a powerful technique called 'retroviral expression cloning' for the identification of oncogenes involved in myeloid leukaemia. In essence our approach is to identify oncogenes from myeloid leukaemia samples on the basis of their function - that is, by virtue of their ability to induce dysregulated or uncontrolled growth of blood-derived cells in culture.